Vildagliptin: a review of its use in type 2 diabetes mellitus (Q37801906)

23 August 2017

Vildagliptin: a review of its use in type 2 diabetes mellitus. (English)

1 reference

23 August 2017

0 references

1

Gillian M Keating

1 reference

23 August 2017

1 November 2010

1 reference

23 August 2017

1 reference

23 August 2017

70

1 reference

23 August 2017

2089-2112

1 reference

23 August 2017

16

1 reference

https://scigraph.springernature.com/pub.10.2165/11206370-000000000-00000

23 August 2017

0 references

cites work

Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11206370-000000000-00000

Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11206370-000000000-00000

Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects

21 January 2018

1 reference

12 December 2020

Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.

1 reference

12 December 2020

Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes

1 reference

12 December 2020

Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus

1 reference

12 December 2020

Vildagliptin in clinical practice: a review of literature.

1 reference

12 December 2020

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

1 reference

12 December 2020

The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.

1 reference

12 December 2020

Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial

1 reference

12 December 2020

Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy

1 reference

12 December 2020

Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database

1 reference

12 December 2020

Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin

1 reference

12 December 2020

Covalent modifiers: an orthogonal approach to drug design

1 reference

12 December 2020

Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.

1 reference

12 December 2020

Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

1 reference

12 December 2020

Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study

1 reference

12 December 2020

Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans

1 reference

12 December 2020

Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet

1 reference

12 December 2020

Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes

1 reference

12 December 2020

Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers

1 reference

12 December 2020

Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*.

1 reference

12 December 2020

Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus

1 reference

12 December 2020

Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year

1 reference

12 December 2020

The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.

1 reference

12 December 2020

Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus

1 reference

12 December 2020

Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes.

1 reference

12 December 2020

Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions

1 reference

12 December 2020

Drug evaluation: vildagliptin-metformin single-tablet combination.

1 reference

12 December 2020

The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers

1 reference

12 December 2020

A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study

1 reference

12 December 2020

DPP-4 inhibitors in clinical practice.

1 reference

12 December 2020

The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.

1 reference

12 December 2020

Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study.

1 reference

12 December 2020

Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial--a primary care, type 2 diabetes study.

1 reference

12 December 2020

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus

1 reference

12 December 2020

Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.

1 reference

12 December 2020

Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia

1 reference

12 December 2020

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

1 reference

12 December 2020

Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study

1 reference

12 December 2020

Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited

1 reference

12 December 2020

The scientific evidence: vildagliptin and the benefits of islet enhancement

1 reference

12 December 2020

Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes.

1 reference

12 December 2020

Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin.

1 reference

12 December 2020

Pharmacodynamics of Vildagliptin in Patients With Type 2 Diabetes During OGTT

1 reference

12 December 2020

Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

1 reference

12 December 2020

Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes

1 reference

12 December 2020

Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use.

1 reference

12 December 2020

Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects

1 reference

12 December 2020

Translating science into clinical practice: focus on vildagliptin in combination with metformin

1 reference

12 December 2020

Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes.

1 reference

12 December 2020

Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study

1 reference

12 December 2020

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

1 reference

12 December 2020

Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes

1 reference

12 December 2020

Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus

1 reference

12 December 2020

NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV

1 reference

12 December 2020

Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

1 reference

12 December 2020

Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema

1 reference

12 December 2020

Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers

1 reference

12 December 2020

An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials

1 reference

12 December 2020

Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers

1 reference

12 December 2020

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

12 December 2020

Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

1 reference

12 December 2020

Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

1 reference

12 December 2020

Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials

1 reference

12 December 2020

Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes

1 reference

12 December 2020

Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations

1 reference

12 December 2020

The islet enhancer vildagliptin: mechanisms of improved glucose metabolism

1 reference

12 December 2020

Bioequivalence of vildagliptin/metformin fixed-dose combination tablets and a free combination of vildagliptin and metformin in healthy subjects

1 reference

12 December 2020

Role of vildagliptin in managing type 2 diabetes mellitus in the elderly

1 reference

12 December 2020

Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes

1 reference

12 December 2020

Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy

1 reference

12 December 2020

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes

1 reference

12 December 2020

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

1 reference

12 December 2020

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.

1 reference

12 December 2020

Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response

1 reference

12 December 2020

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea

1 reference

12 December 2020

Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus

1 reference

12 December 2020

Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy

1 reference

12 December 2020

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

1 reference

12 December 2020

The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin

1 reference

12 December 2020

The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study

1 reference

12 December 2020

10.2165/11206370-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

20964454

Dimensions Publication ID

23 August 2017

0 references

1 reference

PubMed ID

20964454